This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients
EJNMMI Research Open Access 09 December 2020
-
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions
BMC Cancer Open Access 01 October 2020
-
Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade
Journal for ImmunoTherapy of Cancer Open Access 07 May 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science https://doi.org/10.1126/science.aan5951 (2018)
Rights and permissions
About this article
Cite this article
Otto, G. PBRM1 loss promotes tumour response to immunotherapy. Nat Rev Clin Oncol 15, 134–135 (2018). https://doi.org/10.1038/nrclinonc.2018.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2018.12
This article is cited by
-
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions
BMC Cancer (2020)
-
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients
EJNMMI Research (2020)
-
Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade
Journal for ImmunoTherapy of Cancer (2019)